The Cancer Immunogenomics group is highly proficient in employing state-of-the-art technologies including bulk and single cell sequencing, spatial transcriptomics, and single cell and imaging mass cytometry. These approaches provide unprecedented insights into the complex and multicellular nature of cancer microenvironments and the biological processes governing cancer immunity.
We are particularly interested in developing novel immunotherapeutic approaches cancers where current immunotherapeutic approaches are not effective like colorectal cancers with low mutation burden and pancreatic cancers. Recently, we teamed up with the Bone and Soft Tissue research group (PI: Prof.dr. Judith Bovée) to investigate the potential of immunotherapy in bone and soft tissue cancers.
SELECTED PUBLICATIONS
- Sequeira AM, et al.. GRIDGENE: Guided Region Identification based on Density of GENEs–a transcript density-based approach to characterize tissues by spatial transcriptomics. Bioinformatic Advances. 2026; in press. Link
- Van Oost S., et al.. Immune infiltration is associated with distinct transcriptional states and metabolic profiles in chordomas. iScience. 2026; 29 (5). Link
- Nunes JB, Ijsselsteijn ME, et al.. Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling. Nat Methods. 2024;21:1796-1800. Link
- Roelands J, et al.. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut. 2023;72:1326-1339. Link
- de Vries NL*, van de Haar J*, Veninga V*, Chalabi M*, et al.. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature. 2023;613:743-750. Link
